Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells $1,381,980.00 in Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Bruce Cozadd sold 6,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $230.33, for a total value of $1,381,980.00. Following the completion of the sale, the director directly owned 345,875 shares in the company, valued at approximately $79,665,388.75. The trade was a 1.71% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock traded up $0.37 on Monday, reaching $236.04. The company’s stock had a trading volume of 844,577 shares, compared to its average volume of 940,879. The stock’s fifty day simple moving average is $247.07 and its 200-day simple moving average is $229.70. Jazz Pharmaceuticals PLC has a 1 year low of $128.80 and a 1 year high of $266.38. The company has a current ratio of 1.78, a quick ratio of 1.58 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $15.32 billion, a price-to-earnings ratio of 16.28, a price-to-earnings-growth ratio of 0.21 and a beta of 0.37.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 EPS for the quarter, missing the consensus estimate of $6.18 by ($0.47). Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. The business had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.11 billion. During the same quarter last year, the business earned ($8.25) EPS. Jazz Pharmaceuticals’s revenue for the quarter was up 15.5% compared to the same quarter last year. Analysts forecast that Jazz Pharmaceuticals PLC will post 21.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Allianz Asset Management GmbH grew its stake in Jazz Pharmaceuticals by 68.2% during the 4th quarter. Allianz Asset Management GmbH now owns 598,832 shares of the specialty pharmaceutical company’s stock worth $101,801,000 after buying an additional 242,892 shares during the last quarter. Castleark Management LLC acquired a new stake in Jazz Pharmaceuticals in the first quarter worth about $9,214,000. SEB Asset Management AB purchased a new stake in shares of Jazz Pharmaceuticals during the first quarter worth about $8,765,000. Bank of America Corp DE grew its stake in shares of Jazz Pharmaceuticals by 10.9% during the first quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company’s stock worth $191,848,000 after acquiring an additional 99,656 shares during the last quarter. Finally, California Public Employees Retirement System increased its holdings in shares of Jazz Pharmaceuticals by 10.6% during the first quarter. California Public Employees Retirement System now owns 124,583 shares of the specialty pharmaceutical company’s stock valued at $23,552,000 after acquiring an additional 11,915 shares in the last quarter. 89.14% of the stock is owned by institutional investors.

Analysts Set New Price Targets

JAZZ has been the subject of a number of analyst reports. Deutsche Bank Aktiengesellschaft raised their price target on Jazz Pharmaceuticals from $287.00 to $300.00 and gave the stock a “buy” rating in a research report on Wednesday, August 26th. Needham & Company LLC raised their target price on shares of Jazz Pharmaceuticals from $292.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, August 26th. Wells Fargo & Company upped their price target on shares of Jazz Pharmaceuticals from $285.00 to $300.00 and gave the company an “overweight” rating in a report on Tuesday, August 4th. Robert W. Baird raised their price objective on shares of Jazz Pharmaceuticals from $252.00 to $280.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 4th. Finally, The Goldman Sachs Group initiated coverage on Jazz Pharmaceuticals in a research note on Thursday, September 24th. They set a “buy” rating and a $337.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $291.15.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious neurological and oncology-related conditions. Founded in 2003 and headquartered in Dublin, Ireland, the company operates internationally, with a significant commercial presence in the United States and other markets.

Jazz’s neuroscience portfolio includes Xywav and Xyrem, which contain oxybate and are used to treat narcolepsy-related symptoms; Xywav is also approved for idiopathic hypersomnia in adults.